Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 97 in Five Prime Therapeutics

  1. 28 Stocks That Could Double in Two Years No Matter What the Market DoesRead the original story

    Thursday Apr 17 | SBWire

    ... on the low end (chipmaker Intel INTC +0.64%). A few list members - biotech names Dyax DYAX +2.56%, Five Prime Therapeutics and Rigel Pharmaceuticals RIGL +2.56% - aren't expected to be profitable." Instead of directly investing in stocks, many pro ...

    Comment?

  2. Roche Sales Hurt by Strong FrancRead the original story

    Monday Apr 14 | Wall Street Journal

    Swiss drug maker Roche Holding AG reported a 1% dip in first-quarter revenue as the strong Swiss franc eroded the value of growing sales of its cancer drugs.

    Comment?

  3. Five Prime Therapeutics to Present at the 13th Annual Needham Healthcare ConferenceRead the original story

    Tuesday Apr 1 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the 13th Annual Needham Healthcare Conference on April 8, 2014 at 4:20 PM Eastern Time.

    Comment?

  4. Global Protein Therapeutics Market 2012-2016: Patent-Expiration of...Read the original story

    Monday Mar 31 | Customer Interaction Solutions

    Dublin - Research and Markets has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering.

    Comment?

  5. From Lab Bench To Bedside: David Lowe Brings Common Sense To Neuroscience InvestingRead the original story

    Sunday Mar 30 | Seeking Alpha

    In this interview with The Life Sciences Report, David Lowe describes some companies with exciting preclinical and clinical-stage assets that are worthy of investor attention.

    Comment?

  6. Endocyte With Cancer Drug Is Prize Worth Top Premium: Real M&ARead the original story

    Friday Mar 28 | The Washington Post

    Now that Endocyte Inc.'s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry's highest premiums on record.

    Comment?

  7. Endocyte With Cancer Drug Is Prize Worth Top Premium: Real M&ARead the original story

    Friday Mar 28 | The Washington Post

    Now that Endocyte Inc.'s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry's highest premiums on record.

    Comment?

  8. From Lab Bench to Bedside: David Lowe Brings Common Sense to Neuroscience InvestingRead the original story

    Friday Mar 28 | InvestorIdeas.com

    March 28, 2014 Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless.

    Comment?

  9. Five Prime Therapeutics Announces Upcoming Presentations at the 2014...Read the original story

    Thursday Mar 27 | Hispanic Business

    Five Prime has leveraged its comprehensive library of human extracellular proteins and its proprietary high-throughput screening technologies to produce new targets for protein therapeutics to be advanced by partners or in the company's internal pipeline.

    Comment?

  10. The Top Life Sciences Investors Of 2014Read the original story

    Thursday Mar 27 | Forbes.com

    ... to Byers' collection of exits are VeraCyte Inc. (IPO 2013), Foundation Medicine Inc. (IPO 2013), Five Prime Therapeutics Inc. (IPO 2013), Pacific Biosciences of California Inc. (IPO 2010), OptiMedica Corp. (acquired by Abbott Laboratories for $400 ...

    Comment?

  11. 3 Warning Signs the Biotech Rally May Be OverRead the original story w/Photo

    Tuesday Mar 25 | The Motley Fool

    ... with the group gaining an average of 43% for the year! Some have deserved their beefy gains, such as Five Prime Therapeutics , which just last week signed a collaborative deal with Bristol-Myers Squibb allowing the big pharma giant to access its ...

    Comment?

  12. Five Prime Therapeutics, Inc. To Present At In The Biotech IndustryRead the original story

    Friday Mar 21 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 21st Annual Future Leaders in the Biotech ... (more)

    Comment?

  13. Biotech deal could mean $350 million for South San Francisco firmRead the original story

    Mar 17, 2014 | Seattle Post-Intelligencer

    It's deal time Monday for South San Francisco biotech firm Five Prime Therapeutics and New York bio-pharma giant Bristol-Myers Squibb Company in an agreement that could be worth more than $350 milllion for the Bay Area company.

    Comment?

  14. Bristol-Myers Strikes $50M Deal With Five PrimeRead the original story

    Mar 17, 2014 | Pharmaceutical Processing

    Drugmakers Bristol-Myers Squibb and Five Prime Therapeutics said Monday they will work together on experimental immune therapies for cancer.

    Comment?

  15. Bristol-Myers in $50.5M deal with Five PrimeRead the original story

    Mar 17, 2014 | Bioscience Technology

    Drugmakers Bristol-Myers Squibb and Five Prime Therapeutics said Monday they will work together on experimental immune therapies for cancer.

    Comment?

  16. Five Prime deals again: Bristol-Myers Squibb research pact nets cash, equityRead the original story

    Mar 17, 2014 | Business Journal

    ... and CEO Rusty Williams, Five Prime has closed three deals and an IPO over the past five months. Five Prime Therapeutics' latest deal - a potential $350 million-plus collaboration with drug powerhouse Bristol-Myers Squibb Co. focused on booming ...

    Comment?

  17. Bristol-Myers, Five Prime In Cancer PactRead the original story

    Mar 17, 2014 | WRKO-AM Brighton

    Bristol-Myers Squibb made an initial investment of around $50 million to Five Prime Therapeutics as part of an agreement to develop drugs that aim to use the immune system to fight cancer.

    Comment?

  18. Five Prime Therapeutics and BMS to Collaborate on Novel Immuno-Oncology TherapiesRead the original story

    Mar 17, 2014 | Pharmaceutical Processing

    Five Prime Therapeutics and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.

    Comment?

  19. Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration...Read the original story

    Mar 17, 2014 | Business Wire

    SOUTH SAN FRANCISCO & NEW YORK-- --Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's ... (more)

    Comment?

  20. Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company Strike...Read the original story

    Mar 17, 2014 | BioSpace

    Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways SOUTH SAN FRANCISCO & NEW YORK-- -- Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced today that they have signed a collaboration agreement for the discovery, development ... (more)

    Comment?